Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Docetaxel Stories

2013-05-06 12:27:10

At Six Months Post Launch, Almost One Third of Surveyed Urologists have Prescribed Xtandi in Clinical Practice, According to a New Report from BioTrends Research Group EXTON, Pa., May 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists and medical oncologists prescribed...

2013-05-02 16:28:39

Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, May 2, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results. OGX-427 Program Update In January 2013, the Company initiated the ORCA(TM) (Ongoing Studies Evaluating Treatment Resistance...

2013-04-30 08:34:34

The OGX-427 ORCA(TM) Program Continues to Expand with Patient Enrollment Now Open for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, April 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Borealis-2(TM) clinical trial, an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder...

2013-04-25 08:35:32

EAST SETAUKET, N.Y., April 25, 2013 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667. Dr. John...

2013-03-08 23:04:38

A recent FDA-approved combination of therapies used to target HER2-positive breast cancer does not lead to increased cardiac problems for patients, but doctors should regularly perform cardiac monitoring on their cancer patients until additional long-term cardiac safety data become available, according to the first phase III study of the combined treatments. The study, published in The Oncologist, was led by Dr. Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at...

2013-03-07 16:24:46

Conference call to be held on Thursday, March 7, 2013 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, March 7, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today highlighted key clinical development activities for its two product candidates, custirsen and OGX-427, and announced its fourth quarter and year end 2012 financial results. Custirsen Clinical Development Highlights The Company announced completion of patient enrollment of...

2013-02-13 08:27:38

NORTHBROOK, Ill., Feb. 13, 2013 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that more than 10 abstracts from Astellas oncology pipeline agents and marketed products will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), to be held February 14-16 in Orlando, Florida. "We're committed to delivering new treatment options for patients with GU cancers," said...

2013-02-12 20:21:13

ORLANDO, Fla., Feb. 12, 2013 /PRNewswire/ -- Janssen Research & Development, LLC [Janssen] announced today updated results showing ZYTIGA(®) (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer. The Phase 3, randomized, multicenter, placebo-controlled study (COU-AA-302) also demonstrated...

2013-02-12 08:30:20

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 12, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Borealis-2 clinical trial, an investigator-sponsored, randomized, controlled Phase 2 study evaluating OGX-427 in patients with advanced or metastatic bladder cancer who have disease progression following initial platinum-based chemotherapy treatment. The trial, which is the fourth Phase 2 study of OGX-427 in a...

2013-01-10 20:21:52

EXTON, Pa., Jan. 10, 2013 /PRNewswire/ -- Morphotek(®) Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse. The study found that farletuzumab in combination with carboplatin and a taxane did not meet the study's primary endpoint of progression-free survival...